Subacute effusive-constrictive pericarditis in a patient with COVID-19

Rodica Diaconu,1 Lucian Popescu,1 Anda Voicu,1 Ionut Donoiu 2

SUMMARY
We report the case of a previously healthy young woman, who developed a severe form of COVID-19 with massive pneumonia and acute pericarditis in whom constrictive physiology developed rapidly. To our knowledge, this represents the second reported case of SARS-CoV-2 constrictive pericarditis, a rare, but severe cardiac complication.

BACKGROUND
Considered in the beginning a respiratory illness, with the increase in cases it became evident that SARS-CoV-2 infection affects multiple organs, including the heart. The cardiovascular changes range from asymptomatic increase in myocardial injury markers, contractility disorders, arrhythmias, pericardial disease, vascular insufficiency and sudden cardiac arrest. 3 We report the case of a rapidly installed constrictive pericarditis in the setting of COVID-19.

CASE PRESENTATION
A 27-year-old woman presented to the emergency department for fever, dry cough, chest pain and breathlessness. Symptoms started 3 weeks prior with fever and dry cough while working in Germany, where she was tested negative for COVID-19 and received symptomatic treatment. She had no comorbidities but reported a history of personal alcohol abuse in remission for 5 years. She denied a personal history of tuberculosis (TB) or any known tuberculosis contacts. At presentation, she was tachypnoeic (respiratory rate 30/min), oxygen saturation was 90% and auscultation of the lungs revealed diminished breath sound on the left side. Her pulse was 100/min with a blood pressure of 120/70 mm Hg. Auscultation of the heart was normal.

INVESTIGATIONS
The ECG revealed sinus tachycardia, without other changes. Initial laboratory studies revealed mild leucocytosis with lymphopenia, mild thrombocytosis, and elevated inflammatory markers including: D-dimer 5 µg/mL, fibrinogen 653 mg/dL (200–390 mg/dL), ferritin 950 ng/mL (30–400 ng/mL), lactate dehydrogenase 660 U/L (125–220 U/L), C reactive protein 160 mg/L (0–5 mg/L). The liver and kidney function were within normal values. Chest X-ray showed extensive left pulmonary consolidation with moderate pleural effusion and mild tracheal deviation to the right side (figure 1). A CT scan of the chest showed pneumonia in the left lobe with left pleural effusion, and moderate pericardial effusion (figure 2).

TREATMENT
Given the high clinical probability of COVID-19, she was admitted to the isolation unit and retested with COVID-19 real-time reverse transcriptase-PCR (RT-PCR) assay, which came positive this time. She was treated with oxygen, corticosteroids, colchicine, low molecular weight heparin and broad-spectrum antibiotic, for 5 days, without improvement.

OUTCOME AND FOLLOW-UP
Her condition deteriorated progressively with worsening dyspnoea and congestion signs. On day 6, repeated thoracic echocardiogram revealed pericardial thickening with large fibrinous strands traversing the pericardial space and signs of constrictive pericarditis (video 1). The cardiac chamber dimensions were normal with preserved left ventricular ejection fraction and normal heart valves. Mitral inflow velocities demonstrated significant respiratory variation, increased E/A ratio, and rapid E deceleration time. Dilated non-collapsing inferior vena cava (25 mm diameter), but no features of right atrial or right ventricular collapse were noted. Estimated right atrial pressure was elevated (>20 mm Hg) with abnormal movement of the interventricular septum (septal bounce). Thus, a diagnosis of effusive-constrictive pericarditis was made, and the patient was admitted to the intensive care unit for increasing supplemental oxygen requirements. The doses of corticosteroids were increased, and small doses of diuretics were started. A repeated CT scan suggested worsening of pneumonia with bilateral lung involvement and pericardial thickening (figure 3). Troponin was negative and NT-proBNP was 2200 pg/mL. Diagnostic thoracentesis revealed a transudate, with normal adenosine deaminase levels. Pleural fluid and blood cultures were negative. Testing for HIV antibodies and hepatic viruses were negative.

Diagnostic pericardiocentesis was not done because the pericardial effusion seemed localised near the anterolateral left ventricular wall, without effusion next to the right cavities, so the traditional subxiphoid approach could not be used. Because of the associated risk of serious cardiac injury, we did not consider necessary the use of alternative approaches for pericardiocentesis. Based on the transthoracic echocardiogram and clinical symptomatology, the patient had an indication for pericardiectomy, which was delayed because of...
her respiratory complications. Also, cardiac catheterisation for further haemodynamic assessment was not possible. On day 7, she was transferred to a Cardiac Surgery Intensive Care Unit in another hospital. On day 9 from admission, she developed severe respiratory insufficiency with persistent hypoxaemia despite increasing supplemental oxygen requirements, and mechanical ventilation was necessary. The evolution was unfavourable, with severe ARDS and hypoxaemia despite optimised ventilation. On day 14, extracorporeal membrane oxygenation was done but unfortunately, the patient died 5 days later.

DISCUSSION
At present, limited data have been published on pericarditis and pericardial effusion in COVID-19, and only one case of constrictive pericarditis was reported.

Constrictive pericarditis is characterised by inflammation and fibrotic thickening of the parietal and visceral pericardium, causing a restriction in cardiac filling and leading to hypodiastolic heart failure. The most common causes of constrictive pericarditis are cardiac surgery, radiotherapy, tuberculous and purulent pericarditis. Idiopathic and viral pericarditis have a low incidence of constrictive complications.

Constrictive pericarditis is usually a late complication of chronic pericarditis. In rare cases, like the one presented here, it could have a more rapid, subacute evolution. Baker described in 2004 a similar case of a 30-year-old man with acute pericarditis that developed effusive-constrictive physiology in less than 2 weeks. The patient was treated initially with nonsteroidal anti-inflammatory agents and colchicine, but pericardiectomy was needed. The pericardial cavity was filled with fibrinous gelatinous exudates with adhesions to the epicardial surface. Pathological examination noted non-specific findings including fibrosis, chronic inflammation and granulation tissue. The cause of the pericarditis was thought to be idiopathic, presumed viral.

The concept of effusive-constrictive pericarditis was established in 1971 by Hancock. Effusive-constrictive pericarditis is characterised by pericardial effusion, often with cardiac tamponade, and restrictive cardiac filling physiology. Although the gold standard to establish the diagnosis of effusive-constrictive pericarditis has been invasive, involving simultaneous measurement of intrapericardial and intracardiac pressures before and after pericardial drainage, the echocardiography could establish the diagnosis more rapidly.

Echocardiography shows a mixed haemodynamic pattern with elements of constriction and tamponade. The main echocardiographic features are the absence of normalisation in inferior vena cava dilatation and restoration of its respiratory changes, persistently remaining significant respiratory variation of...
the mitral and tricuspid inflow Doppler pattern, abnormal/paradoxic movement of the interventricular septum (septal bounce) and preserved or increased medial mitral c’ velocity.13

Although the pathophysiology of pericarditis in COVID-19 is unknown, it is hypothesised that it occurs secondary to the systemic inflammatory response and the subsequent cytotoxic and immune-mediated effects related to SARS-CoV-2.16 Proinflammatory cytokines (IL-6, TGF-β) and vascular endothelial growth factor (VEGF) released via the associated angiotensin II pathway could promote inflammation and fibrosis of the pericardium in COVID-19 infection.17 18

In developing countries, and this is the case of Romania, TB remains an important cause of pericarditis and it progresses to constriction more frequently than with viral aetologies. In TB constrictive pericarditis pathogenic mechanism are similar, with increased ACE levels, resulting in increased enzymatic cleavage of Ac-SDKP and a subsequent dampening in its antifibrotic potential, which potentially contribute to the pathogenesis of constriction. Also, marked elevations of IL-10 and IFN-γ accompanied by low levels of bioactive TGF-β levels in tuberculous pericardial fluid suggest a Th1 mediated delayed-type hypersensitivity response to the pathogen.19 The lymphocyte Th1 pathway is also involved in COVID-19 infection. It was reported that COVID-19 has higher morbidity and mortality in people with low Th1 immunity.20 In severe cases, studies showed a Th2 response against SARS-CoV-2, rather than a Th1 response.21 New studies are necessary to explain the aggressivity of the virus in some healthy young patients. In our case, the severe evolution could be related to a dysfunction of the innate immune system or by mutations of genes involved in the inflammatory response.

Only one case of SARS-CoV-2 constrictive pericarditis, beside ours, was described in the literature.9 A healthy 29-year-old woman with ARDS developed constrictive pericarditis followed by rapid deterioration of her condition and death. Acute pericarditis could be underdiagnosed in COVID-19 infection. In a study with severe and critical COVID-19 infection, the CT scans described pericardial effusion in 4.8%.22 It is thus important to screen for the presence of pericardial effusion, especially in critically ill patients. Continued observations of the cardiovascular complications of this disease are necessary to fully understand them.

**Learning points**

- **COVID-19 cardiovascular complications are frequent and could be associated with increased mortality and long-term prognostic implications.** It is important to raise awareness for other, more rare complications, such as pericardial effusion.
- **Constrictive pericarditis can occur after any pericardial disease process, but also following acute pericarditis (viral or idiopathic), so it should be suspected in any patient with aggravated symptoms.**
- **This case highlights the potential for patients with COVID-19 to develop life-threatening conditions within a short timeframe.**
- **Patients with moderate or severe forms of COVID-19 should undergo an initial evaluation with an ECG, chest X-ray, and transthoracic echocardiogram.** This may facilitate early diagnosis and management of COVID-19 associated pericarditis which may improve outcomes.

**Twitter** Lucian Popescu @LucianPopescu18

**Contributors** LP, RD, and AV: acquisition of data; drafting the work; final approval; agreement to be accountable for all aspects of the work. ID: design; final revision; final approval; agreement to be accountable for all aspects of the work.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD** Ionut Donoiu http://orcid.org/0000-0001-6338-2657

**REFERENCES**


Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow.